Related Experiment Video

Updated: Jun 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation

Jonathan P Piccini1, Renato D Lopes, Kenneth W Mahaffey

  • 1Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA. jonathan.piccini@duke.edu

Current Opinion in Cardiology
|June 4, 2010
PubMed

Insights

New oral anticoagulants, direct factor Xa inhibitors, show promise for preventing stroke in atrial fibrillation patients. These agents offer effective alternatives to warfarin with favorable safety and efficacy profiles.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Atrial fibrillation management necessitates stroke and systemic emboli prevention.
  • Warfarin, the current standard anticoagulant, has limitations hindering optimal stroke prophylaxis.
  • Research is actively seeking safer and more effective alternatives to warfarin.

Purpose of the Study:

  • To review potential warfarin alternatives in development for atrial fibrillation.
  • To evaluate the safety and efficacy of emerging anticoagulant therapies.
  • To focus on direct factor Xa inhibitors as potential stroke prevention agents.

Main Methods:

  • Review of current research and clinical trials on novel anticoagulants.
  • Evaluation of pharmacokinetic and pharmacodynamic profiles of direct factor Xa inhibitors.
  • Analysis of data from Phase I, II, and III clinical trials.

Main Results:

  • Oral direct factor Xa inhibitors demonstrate potential as well-tolerated warfarin replacements.
  • These agents selectively inhibit factor Xa, a key step in coagulation.
  • Multiple direct factor Xa inhibitors are in late-stage trials, with early results indicating favorable profiles and minimal monitoring needs.

Conclusions:

  • Direct factor Xa inhibitors represent promising alternatives to warfarin for oral anticoagulation in atrial fibrillation.
  • The development of these novel agents is driven by the increasing prevalence of atrial fibrillation.
  • These therapies may improve stroke prevention in a growing patient population.
Abstract

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...